PUBLISHER: The Business Research Company | PRODUCT CODE: 1274450
PUBLISHER: The Business Research Company | PRODUCT CODE: 1274450
“Post-Traumatic Stress Disorder Therapeutics Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on post-traumatic stress disorder therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for post-traumatic stress disorder therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The post-traumatic stress disorder therapeutics market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Major players in the post-traumatic stress disorder therapeutics market are Novartis AG, Pfizer Inc., Bionomics Ltd., Apotex Inc., GlaxoSmithKline PLC., Otsuka Pharmaceutical Co. Ltd., Eli Lilly and Company, Aurobindo Pharma Limited, Merck KGaA, Sun Pharmaceuticals Pvt Ltd., Strategic Behavioral Health, Jazz Pharmaceuticals, Bionomics, Behavioral Health Network Inc., AstraZeneca PLC., Apotex Inc., Prometheon Pharma LLC., Ligand Pharmaceuticals Incorporated, Lycera Corp. and JSC Valenta Pharm.
The global post-traumatic stress disorder therapeutics market is expected to grow from $3.15 billion in 2022 to $3.42 billion in 2023 at a compound annual growth rate (CAGR) of 8.72%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The post-traumatic stress disorder therapeutics market is expected to reach $4.82 billion in 2027 at a CAGR of 8.96%.
The post-traumatic stress disorder therapeutics market consists of revenues earned by entities by providing treatment services such as psychotherapy, medication, and the combination. The market value includes the value of related goods sold by the service provider or included within the service offering. The post-traumatic stress disorder therapeutics market also includes sales of drugs including Sertraline, Paroxetine, and Fluoxetine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Post-traumatic stress disorder therapeutics refers to therapeutics used to treat post-traumatic stress disorder (PTSD), a mental health condition triggered by either experiencing it or witnessing it. Post-traumatic stress disorder treatment helps to improve patients thinking power, changes in physical activity & regain a sense of control over life. The mode of treatment applied for post-traumatic stress disorder includes medication, therapies, self-care & nutrition.
North America was the largest region in the post-traumatic stress disorder therapeutics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The main drugs in post-traumatic stress disorder therapeutics include antidepressants, anti-anxiety, antihypertensive, monoamine oxidase (MAOS), antipsychotics or second-generation antipsychotics (SGOS), beta-blockers, others (benzodiazepines and others). Antidepressants refer to a class of drugs that are used to manage addictions and treat illnesses like major depressive disorder, anxiety disorders, and chronic pain. The age group receiving the therapeutics includes pediatric, geriatric, and adults, by various end users including mental health centers, hospitals, outpatient clinics, and others.
The rise in the burden of post-traumatic stress disorder (PTSD) cases across the globe are expected to propel the growth of the post-traumatic stress disorder therapeutics market going forward. Post-traumatic stress disorder refers to a disorder that develops in people who have experienced a scary, shocking, or dangerous event. Post-traumatic stress disorder treatment such as psychotherapy and medication can help to regain a sense of control over their life. For instance, according to the United States Department of Veterans Affairs, a US-based government department, Nearly 8 million Americans are suffering from PTSD condition in 2021. Hence the rise in the burden of post-traumatic stress disorder (PTSD) cases is driving the growth of the post-traumatic stress disorder therapeutics market.
Strategic collaborations, funding, and investments have emerged as a key trend gaining popularity in the post-traumatic stress disorder therapeutics market. Major companies operating in the market are developing strategic collaborations and investing in the companies to strengthen their position in the market. For instance, in January 2022, Professor Dan Lubman AM, Dr. Shalini Arunogiri, and Dr. Paul Liknaitzky of Monash University, members of an interdisciplinary research team were given over $1.9 million to study the effectiveness of MDMA-assisted psychological treatment for treating alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD). The initiative is one of seven clinical studies under the Medical Research Future Fund (MRFF) unveiled this month by the Federal government to evaluate the use of potentially ground-breaking combination medicines to treat crippling mental diseases.
In October 2020, Jazz Pharmaceuticals Ireland Limited, an Ireland-based biopharmaceutical company acquired SpringWorks' fatty acid amide hydrolase ("FAAH") inhibitor program, including PF-04457845 for an undisclosed amount. Through this acquisition, Jazz will first concentrate on creating PF-04457845 in order to research its potential for treating post-traumatic stress disorder ("PTSD") and its symptoms. SpringWorks is a US-based clinical-stage biopharmaceutical company.
The countries covered in the post-traumatic stress disorder therapeutics market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).
The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.
The post-traumatic stress disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides post-traumatic stress disorder therapeutics market statistics, including post-traumatic stress disorder therapeutics industry global market size, regional shares, competitors with a post-traumatic stress disorder therapeutics market share, detailed sulfuric acid market segments, market trends and opportunities, and any further data you may need to thrive in the post-traumatic stress disorder therapeutics industry. This sulfuric acid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.